NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free PGEN Stock Alerts $1.45 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.42▼$1.4750-Day Range$1.28▼$1.7552-Week Range$0.84▼$1.88Volume676,398 shsAverage Volume1.10 million shsMarket Capitalization$360.93 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Precigen alerts: Email Address Precigen MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside589.7% Upside$10.00 Price TargetShort InterestBearish13.67% of Float Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews Sentiment0.38Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.32) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.87 out of 5 starsMedical Sector186th out of 938 stocksPharmaceutical Preparations Industry78th out of 432 stocks 3.2 Analyst's Opinion Consensus RatingPrecigen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Precigen has a forecasted upside of 589.7% from its current price of $1.45.Amount of Analyst CoveragePrecigen has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.67% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 2.08%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Precigen is -0.77. Previous Next 3.0 News and Social Media Coverage News SentimentPrecigen has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Precigen this week, compared to 2 articles on an average week.Search Interest12 people have searched for PGEN on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows6 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have not sold or bought any company stock.Percentage Held by Insiders41.70% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.51% of the stock of Precigen is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.32) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Precigen Stock (NASDAQ:PGEN)Precigen, Inc. operates as a discovery and clinical stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company, through its technologies, enables to find solutions for biotherapeutics. The company operates as an engine progressing a preclinical and clinical pipeline of therapies toward clinical proof-of-concept and commercialization. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Read More PGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGEN Stock News HeadlinesMarch 28, 2024 | prnewswire.comPrecigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11thMarch 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)March 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 26, 2024 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Upgraded to Sell by StockNews.comMarch 25, 2024 | americanbankingnews.comHC Wainwright Comments on Precigen, Inc.'s FY2026 Earnings (NASDAQ:PGEN)March 23, 2024 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Lowered to Underweight at JPMorgan Chase & Co.March 23, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Precigen, Inc. (NASDAQ:PGEN) Cut by AnalystMarch 22, 2024 | msn.comJ.P. Morgan cuts Precigen to underweight, cites burn rateMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 22, 2024 | americanbankingnews.comPrecigen, Inc. to Post Q1 2025 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:PGEN)March 21, 2024 | bizjournals.comGermantown biotech expands manufacturing capacity, headcount ahead of potential product launchMarch 21, 2024 | americanbankingnews.comPrecigen's (PGEN) Buy Rating Reiterated at HC WainwrightMarch 21, 2024 | americanbankingnews.comPrecigen's (PGEN) "Market Outperform" Rating Reiterated at JMP SecuritiesMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Precigen Amid Promising PRGN-2012 Clinical Progress and Financial StabilityMarch 20, 2024 | finance.yahoo.comPrecigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Taysha Gene Therapies (TSHA)March 19, 2024 | seekingalpha.comPrecigen, Inc. (PGEN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | investorplace.comPGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023March 19, 2024 | finance.yahoo.comPrecigen Inc (PGEN) Reports Full Year 2023 Financial ResultsMarch 19, 2024 | benzinga.comRecap: Precigen Q4 EarningsMarch 19, 2024 | finance.yahoo.comPrecigen Reports Full Year 2023 Financial Results and Business UpdatesMarch 19, 2024 | msn.comUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatMarch 18, 2024 | benzinga.comPreview: Precigen's EarningsMarch 14, 2024 | msn.comAnika Therapeutics to reduce workforce by 9%March 12, 2024 | finance.yahoo.comPrecigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisMarch 8, 2024 | finance.yahoo.comPrecigen, Inc.'s (NASDAQ:PGEN) top owners are private equity firms with 38% stake, while 30% is held by institutionsMarch 5, 2024 | prnewswire.comPrecigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19thSee More Headlines Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PGEN CUSIPN/A CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees209Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$14.00 Low Stock Price Target$6.00 Potential Upside/Downside+589.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,900,000.00 Net Margins-1,540.63% Pretax Margin-1,547.98% Return on Equity-55.47% Return on Assets-43.25% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual Sales$6.22 million Price / Sales58.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.02Miscellaneous Outstanding Shares248,920,000Free Float145,120,000Market Cap$360.93 million OptionableOptionable Beta1.73 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Randal J. Kirk J.D. (Age 71)Executive Chairman Comp: $100kDr. Helen Sabzevari Ph.D. (Age 62)President, CEO & Director Comp: $1.29MMr. Harry Thomasian Jr. (Age 61)Chief Financial Officer Comp: $524.04kMr. Rutul R. Shah (Age 43)Chief Operating Officer Comp: $393.54kMr. Donald P. Lehr (Age 49)Chief Legal Officer & Corporate Secretary Comp: $652.4kMr. Jeffrey Thomas Perez (Age 52)Senior Vice President of Intellectual Property Affairs Comp: $570.24kMr. Steven HarasymVP & Head of Investor RelationsMr. Rob RussellVP & Head of Human ResourcesDr. Douglas E. Brough Ph.D. (Age 69)Senior VP & Head of Research Dr. Bryan T. Butman Ph.D. (Age 71)Senior VP & Head of CMC More ExecutivesKey CompetitorsVentyx BiosciencesNASDAQ:VTYXOrganogenesisNASDAQ:ORGOAmarinNASDAQ:AMRNUroGen PharmaNASDAQ:URGNFibroBiologicsNASDAQ:FBLGView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 202,515 shares on 3/11/2024Ownership: 2.711%Fisher Asset Management LLCBought 21,800 shares on 3/5/2024Ownership: 0.009%Goldman Sachs Group Inc.Sold 99,784 shares on 3/1/2024Ownership: 0.115%Virtu Financial LLCBought 65,526 shares on 2/26/2024Ownership: 0.026%MSD Partners L.P.Sold 605,000 shares on 2/20/2024Ownership: 0.143%View All Insider TransactionsView All Institutional Transactions PGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Precigen stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGEN, but not buy additional shares or sell existing shares. View PGEN analyst ratings or view top-rated stocks. What is Precigen's stock price target for 2024? 3 brokerages have issued 12-month price objectives for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 589.7% from the stock's current price. View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts. How have PGEN shares performed in 2024? Precigen's stock was trading at $1.34 at the beginning of 2024. Since then, PGEN stock has increased by 8.2% and is now trading at $1.45. View the best growth stocks for 2024 here. When is Precigen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PGEN earnings forecast. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) announced its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.01. The biotechnology company earned $21.56 million during the quarter, compared to analyst estimates of $24.47 million. Precigen had a negative net margin of 1,540.63% and a negative trailing twelve-month return on equity of 55.47%. What ETF holds Precigen's stock? Virtus LifeSci Biotech Clinical Trials ETF holds 87,692 shares of PGEN stock, representing 0.90% of its portfolio. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC). Who are Precigen's major shareholders? Precigen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Patient Capital Management LLC (6.42%), Vanguard Group Inc. (2.71%), Vanguard Group Inc. (2.71%), Iridian Asset Management LLC CT (0.81%), Northern Trust Corp (0.43%) and Opaleye Management Inc. (0.41%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rutul R Shah, Steven Frank and Trading SA Ares. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PGEN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.